皮膚扁平上皮がん（cSCC）の世界市場レポート 2025年

皮膚扁平上皮がん（cSCC）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で99億米ドルに成長します。予測期間の成長は、標的治療薬の利用可能性の増加、皮膚がん予防に対する意識の高まり、がん治療のための医療ツーリズムの拡大、低侵襲手術の採用増加、がん治療に対する政府の支援イニシアティブなどに起因すると考えられます。この期間の主な動向としては、皮膚科診断の進歩、高度な放射線治療技術の開発、皮膚科における技術統合の進展、免疫療法治療の革新、光線力学療法の進歩などが挙げられます。

皮膚がんに対する意識の高まりが皮膚扁平上皮がん（cSCC）市場の成長を牽引すると予想されます。皮膚細胞の異常増殖によって生じる皮膚がんは、紫外線への過剰な曝露によって引き起こされることが多く、良性のものから生命を脅かすものまでさまざまです。皮膚がんに対する認識が高まっている背景には、公衆衛生キャンペーンの拡大、情報へのアクセスの改善、早期発見と予防の重視があり、診断・治療ソリューションに対する需要の高まりにつながっています。皮膚扁平上皮がん（cSCC）は、標的治療を可能にし、診断精度を向上させ、患者の転帰を改善し、最終的にはより良い疾患管理をサポートすることで、皮膚がん治療の進歩に重要な役割を果たしています。例えば、2024年1月、米国を拠点とするがん撲滅のための非営利団体である米国がん協会（American Cancer Society）は、2023年の皮膚がん患者数を10万4,930人と報告し、2022年の10万8,270人から3.2％増加しました。その結果、皮膚がんに対する意識の高まりが皮膚扁平上皮がん（cSCC）市場の拡大を後押しすると予想されます。

皮膚扁平上皮がん（cSCC）市場の主要企業は、患者の転帰を改善し、進行皮膚がんを管理するためのより効果的なソリューションを提供するために、PD-L1阻害剤や標的治療などの免疫腫瘍学治療の進歩を重視しています。PD-L1（プログラム死リガンド1）は、T細胞上のPD-1受容体に結合するタンパク質で、免疫反応を抑制し、がん細胞が免疫の検出を回避することを可能にします。2024年12月、米国のバイオテクノロジー企業であるCheckpoint Therapeutics Inc.は、PD-L1を阻害することで免疫系のがんに対する能力を高める新規治療薬Unloxcyt（cosibelimab-ipdl）のFDA承認を取得しました。この治療法は、より安全で効果的な治療の選択肢を提供するものであり、その二重の作用機序により、進行した皮膚扁平上皮がん（cSCC）を管理するための有望なアプローチとなります。今回の承認は、進行cSCC患者において臨床的に意義のある客観的奏効率と持続的奏効を示したCK-301-101試験の結果に基づいています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界皮膚扁平上皮がん（cSCC） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の皮膚扁平上皮がん（cSCC）市場：成長率分析
• 世界の皮膚扁平上皮がん（cSCC）市場の実績：規模と成長, 2019-2024
• 世界の皮膚扁平上皮がん（cSCC）市場の予測：規模と成長, 2024-2029, 2034F
• 世界皮膚扁平上皮がん（cSCC）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の皮膚扁平上皮がん（cSCC）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外科的治療
• 非外科的治療
• 世界の皮膚扁平上皮がん（cSCC）市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コンピュータ断層撮影（CT）
• 磁気共鳴画像法（MRI）
• 生検
• 世界の皮膚扁平上皮がん（cSCC）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん研究所
• 外来手術センター
• その他の用途
• 世界の皮膚扁平上皮がん（cSCC）市場、外科的治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 切除手術
• モーズ顕微鏡手術
• 掻爬術と電気乾燥術
• 世界の皮膚扁平上皮がん（cSCC）市場、非外科的治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線治療
• 凍結療法
• 光線力学療法
• 局所療法
• 全身療法

第7章 地域別・国別分析

• 世界の皮膚扁平上皮がん（cSCC）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の皮膚扁平上皮がん（cSCC）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 皮膚扁平上皮がん（cSCC）市場：競合情勢
• 皮膚扁平上皮がん（cSCC）市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• 3M Company
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Incyte Corporation
• Hikma Pharmaceuticals plc
• Shanghai Henlius Biotech Inc.
• Fortress Biotech Inc.
• Rakuten Medical Inc.
• Morphogenesis Inc.
• CureVac N.V.
• Vidac Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 皮膚扁平上皮がん（cSCC）市場2029：新たな機会を提供する国
• 皮膚扁平上皮がん（cSCC）市場2029：新たな機会を提供するセグメント
• 皮膚扁平上皮がん（cSCC）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cutaneous squamous cell carcinoma (cSCC) is a form of skin cancer that originates in the squamous cells of the skin's outer layer. It most often develops in sun-exposed areas and can present as localized lesions or evolve into more aggressive forms that may metastasize to other parts of the body.

The primary treatment modalities for cSCC include both surgical and non-surgical approaches. Surgical treatments involve the removal of cancerous cells through techniques such as excision or Mohs surgery, aiming to completely eliminate the tumor while minimizing damage to surrounding healthy tissue. Diagnostic methods encompass computed tomography (CT), magnetic resonance imaging (MRI), and biopsy, which are employed across various settings such as hospitals, cancer institutes, ambulatory surgical centers, and more.

The cutaneous squamous cell carcinoma (cSCC) market research report is one of a series of new reports from The Business Research Company that provides cutaneous squamous cell carcinoma (cSCC) market statistics, including the cutaneous squamous cell carcinoma (cSCC) industry global market size, regional shares, competitors with the cutaneous squamous cell carcinoma (cSCC) market share, detailed cutaneous squamous cell carcinoma (cSCC) market segments, market trends, and opportunities, and any further data you may need to thrive in the cutaneous squamous cell carcinoma (cSCC) industry. This cutaneous squamous cell carcinoma (cSCC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cutaneous squamous cell carcinoma (cSCC) market size has grown strongly in recent years. It will grow from $7.45 billion in 2024 to $7.90 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historic period can be attributed to the rising prevalence of non-melanoma skin cancers, an expanding elderly population, increased exposure to ultraviolet radiation, improvements in healthcare infrastructure, and the growing use of immunotherapy in oncology.

The cutaneous squamous cell carcinoma (cSCC) market size is expected to see strong growth in the next few years. It will grow to $9.90 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing availability of targeted therapies, heightened awareness of skin cancer prevention, the expansion of medical tourism for cancer treatments, the rising adoption of minimally invasive surgeries, and supportive government initiatives for cancer care. Major trends during this period include advancements in dermatology diagnostics, the development of advanced radiotherapy techniques, greater technological integration in dermatology, innovations in immunotherapy treatments, and progress in photodynamic therapy.

The increasing awareness of skin cancer is expected to drive the growth of the cutaneous squamous cell carcinoma (cSCC) market. Skin cancer, which results from the abnormal growth of skin cells, is often caused by excessive exposure to UV radiation and can range from benign to life-threatening. The rising awareness of skin cancer is attributed to expanded public health campaigns, improved access to information, and a stronger emphasis on early detection and prevention, leading to a higher demand for diagnostic and treatment solutions. Cutaneous squamous cell carcinoma (cSCC) plays a vital role in advancing skin cancer care by enabling targeted therapies, improving diagnostic accuracy, and enhancing patient outcomes, ultimately supporting better disease management. For example, in January 2024, the American Cancer Society, a US-based nonprofit organization dedicated to eliminating cancer, reported 104,930 cases of skin cancer in 2023, marking a 3.2% increase from the 108,270 cases recorded in 2022. As a result, the growing awareness of skin cancer is expected to boost the expansion of the cutaneous squamous cell carcinoma (cSCC) market.

Leading companies in the cutaneous squamous cell carcinoma (cSCC) market are emphasizing advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted treatments, to improve patient outcomes and provide more effective solutions for managing advanced skin cancer. PD-L1, or programmed death-ligand 1, is a protein that binds to PD-1 receptors on T-cells, suppressing the immune response and enabling cancer cells to evade immune detection. In December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, received FDA approval for Unloxcyt (cosibelimab-ipdl), a novel treatment designed to block PD-L1, thereby enhancing the immune system's ability to combat cancer. This therapy offers a safer and more effective treatment option, with its dual mechanisms of action providing a promising approach for managing advanced cutaneous squamous cell carcinoma (cSCC). The approval was based on findings from the CK-301-101 trial, which demonstrated clinically meaningful objective response rates and durable responses in patients with advanced cSCC.

In May 2022, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Checkmate Pharmaceuticals for an undisclosed sum. This acquisition is intended to strengthen Regeneron's focus on immuno-oncology by integrating vidutolimod, a promising clinical asset, alongside an innovative virus-like particle (VLP) delivery system. The addition of this technology enhances Regeneron's portfolio of combination-ready strategies for treating difficult-to-manage cancers. Checkmate Pharmaceuticals Inc. is a US-based clinical-stage biotechnology company specializing in therapeutics for cutaneous squamous cell carcinoma.

Major players in the cutaneous squamous cell carcinoma (cSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.

North America was the largest region in the cutaneous squamous cell carcinoma (cSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cutaneous squamous cell carcinoma (cSCC) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Cutaneous Squamous Cell Carcinoma (cSCC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cutaneous squamous cell carcinoma (cSCC) market consists of revenues earned by providing radiation therapy, chemotherapy services, immunotherapy and targeted therapy services, diagnostic services, and follow-up and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cutaneous squamous cell carcinoma (CsCC) market also includes sales of topical treatments such as 5-fluorouracil, imiquimod, monoclonal antibodies, and vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cutaneous Squamous Cell Carcinoma (cSCC) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cutaneous squamous cell carcinoma (cscc) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cutaneous squamous cell carcinoma (cscc) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cutaneous squamous cell carcinoma (cscc) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Surgical Treatment; Non-Surgical Treatment
• 2) By Diagnosis: Computed Tomography (CT); Magnetic Resonance Imaging (MRI); Biopsy
• 3) By Application: Hospitals; Cancer Institutes; Ambulatory Surgical Centers; Other Applications
• Subsegments:
• 1) By Surgical Treatment: Excisional Surgery; Mohs Micrographic Surgery; Curettage And Electrodessication
• 2) By Non-Surgical Treatment: Radiation Therapy; Cryotherapy; Photodynamic Therapy; Topical Therapies; Systemic Therapies
• Companies Mentioned: F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cutaneous Squamous Cell Carcinoma (cSCC) Market Characteristics

3. Cutaneous Squamous Cell Carcinoma (cSCC) Market Trends And Strategies

4. Cutaneous Squamous Cell Carcinoma (cSCC) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cutaneous Squamous Cell Carcinoma (cSCC) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cutaneous Squamous Cell Carcinoma (cSCC) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market Growth Rate Analysis
• 5.4. Global Cutaneous Squamous Cell Carcinoma (cSCC) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cutaneous Squamous Cell Carcinoma (cSCC) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cutaneous Squamous Cell Carcinoma (cSCC) Total Addressable Market (TAM)

6. Cutaneous Squamous Cell Carcinoma (cSCC) Market Segmentation

• 6.1. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgical Treatment
• Non-Surgical Treatment
• 6.2. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Biopsy
• 6.3. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Institutes
• Ambulatory Surgical Centers
• Other Applications
• 6.4. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Sub-Segmentation Of Surgical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Excisional Surgery
• Mohs Micrographic Surgery
• Curettage And Electrodessication
• 6.5. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Sub-Segmentation Of Non-Surgical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiation Therapy
• Cryotherapy
• Photodynamic Therapy
• Topical Therapies
• Systemic Therapies

7. Cutaneous Squamous Cell Carcinoma (cSCC) Market Regional And Country Analysis

• 7.1. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 8.1. Asia-Pacific Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 9.1. China Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 9.2. China Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 10.1. India Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 11.1. Japan Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 11.2. Japan Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 12.1. Australia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 13.1. Indonesia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 14.1. South Korea Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 14.2. South Korea Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 15.1. Western Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 15.2. Western Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 16.1. UK Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 17.1. Germany Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 18.1. France Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 19.1. Italy Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 20.1. Spain Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 21.1. Eastern Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 21.2. Eastern Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 22.1. Russia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 23.1. North America Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 23.2. North America Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 24.1. USA Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 24.2. USA Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 25.1. Canada Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 25.2. Canada Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 26.1. South America Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 26.2. South America Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 27.1. Brazil Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 28.1. Middle East Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 28.2. Middle East Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cutaneous Squamous Cell Carcinoma (cSCC) Market

• 29.1. Africa Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview
• 29.2. Africa Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cutaneous Squamous Cell Carcinoma (cSCC) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cutaneous Squamous Cell Carcinoma (cSCC) Market Competitive Landscape And Company Profiles

• 30.1. Cutaneous Squamous Cell Carcinoma (cSCC) Market Competitive Landscape
• 30.2. Cutaneous Squamous Cell Carcinoma (cSCC) Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Cutaneous Squamous Cell Carcinoma (cSCC) Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. 3M Company
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Incyte Corporation
• 31.9. Hikma Pharmaceuticals plc
• 31.10. Shanghai Henlius Biotech Inc.
• 31.11. Fortress Biotech Inc.
• 31.12. Rakuten Medical Inc.
• 31.13. Morphogenesis Inc.
• 31.14. CureVac N.V.
• 31.15. Vidac Pharma Inc.

32. Global Cutaneous Squamous Cell Carcinoma (cSCC) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cutaneous Squamous Cell Carcinoma (cSCC) Market

34. Recent Developments In The Cutaneous Squamous Cell Carcinoma (cSCC) Market

35. Cutaneous Squamous Cell Carcinoma (cSCC) Market High Potential Countries, Segments and Strategies

• 35.1 Cutaneous Squamous Cell Carcinoma (cSCC) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cutaneous Squamous Cell Carcinoma (cSCC) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cutaneous Squamous Cell Carcinoma (cSCC) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer